Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio , a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for MRT5500, a mRNA-based vaccine candidate against SARS-CoV-2, the virus that causes COVID-19 disease.
Preclinical evaluation of MRT5500, importantly, demonstrated a favorable immune response profile against SARS-CoV-2. These data support the selection of MRT5500 for clinical development. A Phase 1/2 clinical trial is anticipated to begin in the fourth quarter of 2020. Full results are available here. MRT5500 is being developed under a collaboration agreement between Sanofi Pasteur and Translate Bio.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-09-05
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Which Protein Is Present In Covid 19
-
Which Is The Best Covid Vaccine In The World
-
Interpretation Of Omicron Covid Variant Symptoms
-
A Look At The Worst Hit Covid Countries
-
Nitric Oxide Nasal Spray Prevents Spread of Coronavirus, Clinical Trials Show
-
'Delta MayJust Be A Warning', New Variant Of COVID-19 May Emerge
-
What Other Vaccines Use mRNA And The Application Of Homogeneous Technology In mRNA Vaccine And Drug Development.
-
Does Vaccine Protect Against Omicron? Zhang Wenhong : Vaccination Booster Is Still An Effective Tool To Deal With Omicron
-
Shanghai Company's Self-Developed COVID-19 mRNA Vaccine Approved For Clinical Trials And mRNA Vaccines Animal Trials
-
mRNA Vaccine Production Process : LNP Delivery Technology
Recommend Reading
-
![Profit Soars While Sales Dip: Syngenta Group Defies Headwinds with 28% EBITDA Surge in Q3 2025]()
Profit Soars While Sales Dip: Syngenta Group Defies Headwinds with 28% EBITDA Surge in Q3 2025
-
![Growing Pains, But the Roots Are Strong: Corteva Narrows Losses Amid Sales Surge in Q3 2025]()
Growing Pains, But the Roots Are Strong: Corteva Narrows Losses Amid Sales Surge in Q3 2025
-
![From the Brink to the Bend: Bayer’s Q3 2025 Shows Dramatic Loss Reduction—but Crop Science Still Bleeds]()
From the Brink to the Bend: Bayer’s Q3 2025 Shows Dramatic Loss Reduction—but Crop Science Still Bleeds
-
![Yara’s Green Surge: Record Profits Fuelled by Precision, Not Just Prices]()
Yara’s Green Surge: Record Profits Fuelled by Precision, Not Just Prices
-
![From Modest Gains to Massive Profits: Nutrien’s Q3 2025 Marks a Stunning Agricultural Comeback]()
From Modest Gains to Massive Profits: Nutrien’s Q3 2025 Marks a Stunning Agricultural Comeback
-
![In Mid-August, the Phosphate Market in China Experienced a Slight Decline (8.11-8.19)]()
In Mid-August, the Phosphate Market in China Experienced a Slight Decline (8.11-8.19)
-
![Nature’s Blueprint, Science’s Edge: Corteva Unveils Twin Breakthroughs to Tackle the $70 Billion Insect Threat]()
Nature’s Blueprint, Science’s Edge: Corteva Unveils Twin Breakthroughs to Tackle the $70 Billion Insect Threat
-
![This Week's Styrene Market Fluctuates within a Range (11.17-11.21)]()
This Week's Styrene Market Fluctuates within a Range (11.17-11.21)
-
![Business Society’s Market Outlook for Epichlorohydrin on August 19, 2026: Clearly Downward]()
Business Society’s Market Outlook for Epichlorohydrin on August 19, 2026: Clearly Downward
-
![This Week's TDI Market Stabilizes (11.17-11.21)]()
This Week's TDI Market Stabilizes (11.17-11.21)
